Abstract:Abstract Glioblastoma (GBM) is considered highly radioresistant. To improve the efficacy of GBM radiotherapy, one approach is the addition of a targeted radiosensitizer, which requires an understanding of the molecules that determine GBM radioresponse. Along these lines, PRMT5 is a type II arginine methyltransferase that symmetrically dimethylates histone and non-histone substrates to regulate chromatin structure and mRNA splicing, two parameters that can influence radiosensitivity. As an initial test of PRMT5 as a target for GBM radiosensitization, PRMT5 knockdown using siRNA was shown to increase the in vitro radiosensitivity of U251 GBM cells. PRMT5 was then targeted using the small molecule inhibitor LLY-283, which penetrates the blood brain barrier. Exposure of U251 cells to LLY-283 (24h) reduced the levels of symmetric dimethylated arginine as determined by western blot, indicating an inhibition of PRMT5 activity. Based on clonogenic analysis, LLY-283 exposure beginning 1h prior to irradiation significantly enhanced the radiosensitivity of U251 cells. Whereas treatment of the normal fibroblast cell line MRC9 with LLY-283 reduced PRMT5 activity, no effect was detected on radiosensitivity, suggesting tumor cell selective radiosensitization. As an initial investigation of the radiosensitizing mechanism, U251 were treated with LLY-283 1h prior irradiation (2Gy) and the number of γH2AX foci, marker for DNA double strand breaks (DSBs), was determined. Whereas LLY-283 had no effect on the initial level of radiation-induced γH2AX foci, the dispersal of foci was significantly delayed in LLY-283 treated cells. These results suggest that LLY-283 inhibits the repair of radiation-induced DSBs. The neutral comet assay, an alternative measure of radiation-induced DSBs showed that LLY-283 delivered 1h prior irradiation (10Gy) significantly increased the comet tail moment detected at 6 and 24h as compared to 10Gy only, consistent with an inhibition of DSB repair. Based on these two approaches LLY-283-induced radiosensitization appears to be mediated by an inhibition of DSB repair. Extending these studies to GBM stem-like cell lines (GSCs) showed that LLY-283 inhibited PRMT5 activity and when delivered 1h prior to irradiation enhanced radiosensitivity. Analysis of γH2AX foci showed a delay in foci dispersal in LLY-283 treated cells consistent with an inhibition of DSB repair. Because a 1h LLY-283 pretreatment was sufficient for the inhibition of DSB repair and enhanced radiosensitivity, it appears that the radiosensitization was primarily the result of altered chromatin function rather than changes in gene expression due to alternative mRNA splicing. Altogether, these results suggest targeting PRMT5 as a potential strategy for enhancing the radiosensitivity of GBMs. Citation Format: Charlotte M. Degorre, Steven Lohard, Philip J. Tofilon. Targeting prmt5 inhibits DNA repair and enhances the radiosensitivity of GBM cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2406.

PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells

Tmic-76. Prmt5 Modulates T Cell Proliferation In Glioblastoma Tumor Microenvironment

PRMT5 inhibition disrupts splicing and stemness in glioblastoma

Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.

PRMT5 maintains tumor stem cells to promote pediatric high-grade glioma tumorigenesis

HGG-20. PRMT5 promotes the formation and growth of pediatric high-grade glioma by maintaining tumor stem cell populations

Abstract 1829: Characterization of factors affecting sensitivity and resistance to PRMT5 inhibition in glioblastoma

PRMT3 drives glioblastoma progression by enhancing HIF1A and glycolytic metabolism

PRMT2 Links Histone H3R8 Asymmetric Dimethylation to Oncogenic Activation and Tumorigenesis of Glioblastoma

Abstract 2406: Targeting prmt5 inhibits DNA repair and enhances the radiosensitivity of GBM cells

Silencing of PRDM5 Increases Cell Proliferation and Inhibits Cell Apoptosis in Glioma

Glioblastoma with PRMT5 gene upregulation is a key target for tumor cell regression

PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo

PRMT6-CDC20 Facilitates Glioblastoma Progression Via the Degradation of CDKN1B

PRMT5 Promotes Epithelial‐mesenchymal Transition Via EGFR‐β‐catenin Axis in Pancreatic Cancer Cells

PRMT1 Promotes Neuroblastoma Cell Survival Through ATF5.

PRMT5 as a Potential Therapeutic Target in MYC-Amplified Medulloblastoma

The interplay mechanism between IDH mutation, MGMT-promoter methylation, and PRMT5 activity in the progression of grade 4 astrocytoma: unraveling the complex triad theory

Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing

Abstract 1725: Role of PRMT5 in neuroendocrine prostate cancer development

PTEN regulates expression of its pseudogene in glioblastoma cells in DNA methylation-dependent manner